Omeros (LTS:0KBU) E10: $-1.20 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0KBU Omeros Corp LTS:0KBU
34 GF Score
Price $19.12
! 6 Warning Signs
View Full Analysis

What is Omeros E10?

Omeros LTS:0KBU +4.36% 34 E10 is $-1.20 as of Jun. 2026. GuruFocus rates LTS:0KBU with a GF Score™ of 34/100. The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Omeros's adjusted earnings per share data for the three months ended in Jun. 2026 was $0.150. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.20 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average E10 Growth Rate was 2.60% per year. During the past 5 years, the average E10 Growth Rate was 5.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Omeros was 10.80% per year. The lowest was 2.10% per year. And the median was 7.90% per year.

As of today (2026-08-22), Omeros's current stock price is $19.12. Omeros's E10 for the quarter that ended in Jun. 2026 was $-1.20. Omeros's Shiller PE Ratio of today is .


Omeros  (LTS:0KBU) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Omeros E10 Related Terms


Omeros E10 Historical Data

* Premium members only.

The historical data trend for Omeros's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros E10 Chart

Omeros Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.74 -1.40 -1.47 -1.45 -1.33

Omeros Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.58 -1.53 -1.33 -1.20 -1.20

LTS:0KBU vs STTK, BBOT, XOMA: E10 Comparison

For the Biotechnology subindustry, Omeros's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omeros Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Omeros's Shiller PE Ratio falls into.


LTS:0KBU
34GF Score
Omeros Corp LTS:0KBU
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omeros E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Omeros's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.15/333.9520*333.9520
=0.150

Current CPI (Jun. 2026) = 333.9520.

Omeros Quarterly Data

per share eps CPI Adj_EPS
201609 -0.340 241.428 -0.470
201612 -0.450 241.432 -0.622
201703 -0.340 243.801 -0.466
201706 -0.330 244.955 -0.450
201709 -0.160 246.819 -0.216
201712 -0.340 246.524 -0.461
201803 -0.620 249.554 -0.830
201806 -0.700 251.989 -0.928
201809 -0.810 252.439 -1.072
201812 -0.480 251.233 -0.638
201903 -0.500 254.202 -0.657
201906 -0.290 256.143 -0.378
201909 -0.330 256.759 -0.429
201912 -0.580 256.974 -0.754
202003 -0.530 258.115 -0.686
202006 -0.610 257.797 -0.790
202009 -0.660 260.280 -0.847
202012 -0.600 260.474 -0.769
202103 -0.570 264.877 -0.719
202106 -0.460 271.696 -0.565
202109 -0.360 274.310 -0.438
202112 4.480 278.802 5.366
202203 -0.530 287.504 -0.616
202206 -0.490 296.311 -0.552
202209 -0.280 296.808 -0.315
202212 2.050 296.797 2.307
202303 -0.540 301.836 -0.597
202306 -0.590 305.109 -0.646
202309 -0.600 307.789 -0.651
202312 -0.150 306.746 -0.163
202403 -0.630 312.332 -0.674
202406 -0.970 314.175 -1.031
202409 -0.560 315.301 -0.593
202412 -0.540 315.605 -0.571
202503 -0.580 319.799 -0.606
202506 -0.430 322.561 -0.445
202509 -0.470 324.800 -0.483
202512 0.980 324.054 1.010
202603 0.620 330.213 0.627
202606 0.150 333.952 0.150

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.20 mean?
Omeros (LTS:0KBU) has a E10 of $-1.20 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Omeros and its competitors.
Is Omeros' E10 too high?
Omeros' current E10 is $-1.20. Overall, Omeros has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Omeros' E10 compare to STTK and BBOT?
Omeros' E10 of $-1.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Omeros and its competitors. Omeros's current E10 is $-1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omeros stock overvalued right now?
Omeros (LTS:0KBU) has a current E10 of $-1.20. The current E10 is $-1.20. Omeros' overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Omeros (LTS:0KBU), the current E10 is $-1.20 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Omeros Business Description

Other Exchanges OMER:USA3O8:Germany
Address 201 Elliott Avenue West, Seattle, WA, USA, 98119
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
34GF Score

Get the complete analysis for LTS:0KBU

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.12
Price